According to the internet, Bear Grylls, the TV survivalist, said he “was always brought up to have a cup of tea at halfway up a rock face.” Which sounds too cute to be true and, given Grylls’ history of, um, buffing the hard edges of reality, almost certainly isn’t. But Grylls appears to be far … Continue reading Maybe combining red wine and tea doesn’t kill tumors after all
Elsevier is looking into how one of its journals published a paper which makes bizarre claims about the knowledge of the ancients and contains an acronym with unmistakable and horrific historical significance. The article, “Puratana Aakasha-Yantrika Nirmana Sadhanavasthu (Ancient Aero-mechanical manufacturing materials),” appeared in a 2017 issue of Materials Today Proceedings and was written by … Continue reading Elsevier looking into how “unorthodox” paper featuring ancient astronauts was published
We have news of two upcoming retractions, both following critiques on PubPeer. PLOS ONE is retracting a 2012 paper by researchers at the Istituto Superiore di Sanità in Rome and the World Health Organization’s International Agency for Research on Cancer in Lyon, France, “Interferon-β Induces Cellular Senescence in Cutaneous Human Papilloma Virus-Transformed Human Keratinocytes by … Continue reading “All very painful:” Two retractions to watch for, in eLife and PLOS ONE
Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance. The week at Retraction Watch featured plagiarism by a priest; retraction of a creationist paper “published … Continue reading Weekend reads: Journal editor fired for homophobic comments; “three-parent baby” paper mega-correction; the Bette Midler journal club
A pair of business researchers in Pittsburgh has lost a controversial 2017 paper on how institutional stock holdings affect tax strategies amid concerns about the validity of the data. The article, “Governance and taxes: evidence from regression discontinuity,” which appeared in The Accounting Review, was written by Andrew Bird and Stephen Karolyi, of Carnegie Mellon’s … Continue reading After more than a year of back and forth, an accounting journal retracts a paper on tax avoidance
Before we present this week’s Weekend Reads, a question: Do you enjoy our weekly roundup? If so, we could really use your help. Would you consider a tax-deductible donation to support Weekend Reads, and our daily work? Thanks in advance. The week at Retraction Watch featured the retraction of a paper by a journalist in Australia … Continue reading Weekend reads: Conflict of interest debate roils on; fake peer review scams; amateur hour at journals
The Journal of Biological Chemistry (JBC) has retracted a 2003 paper that resulted from the PhD thesis of Maryanne Demasi, an Australian journalist whose reporting on statins and the risks of cancer from cell phones has been a lightning rod. The move, for what the journal says was attempts to reuse images to represent different … Continue reading Journal retracts paper by controversial Australian journalist
A former postdoc at the University of Michigan admitted to research misconduct, but lied about how extensive it was, according to a new finding by the U.S. Office of Research Integrity (ORI). The ORI doesn’t describe Venkata Sudheer Kumar Ramadugu‘s misconduct — that detail will likely come later in the Federal Register, according to their … Continue reading Former UMich postdoc earns five-year ban on Federal funding, after admitting to misconduct and then lying
A pair of researchers at the Indian Institute of Technology (Indian School of Mines) has had a total of nine more papers retracted, pushing their totals to 24 and 26, respectively. The totals put the two researchers — Rashmi Madhuri, with 24 retractions, and Prashant Sharma, with 26 — on our leaderboard of the 30 … Continue reading Pair of nanotech researchers up to at least two dozen retractions
The chief scientific officer of a cannabis product company whose stock price has been hotter than a flaming joint (sorry) was known more than 18 months ago to have committed research misconduct while at the U.S. National Institutes of Health — casting a cloud of suspicion over the firm’s operations. Marketwatch reported yesterday that the … Continue reading Chief scientific officer of a high-flying cannabis product company faked data at the NIH